ESSA Pharma (NASDAQ:EPIX – Get Free Report) (TSE:EPI) is expected to be posting its quarterly earnings results before the market opens on Tuesday, February 11th. Analysts expect ESSA Pharma to post earnings of ($0.18) per share for the quarter.
ESSA Pharma (NASDAQ:EPIX – Get Free Report) (TSE:EPI) last announced its quarterly earnings data on Tuesday, December 17th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.05. On average, analysts expect ESSA Pharma to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
ESSA Pharma Stock Performance
Shares of ESSA Pharma stock opened at $1.69 on Monday. ESSA Pharma has a twelve month low of $1.40 and a twelve month high of $10.97. The firm has a market cap of $75.02 million, a P/E ratio of -2.64 and a beta of 1.60. The firm’s 50-day simple moving average is $1.72 and its 200-day simple moving average is $3.71.
Analyst Ratings Changes
View Our Latest Stock Analysis on ESSA Pharma
ESSA Pharma Company Profile
ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company’s lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.
Further Reading
- Five stocks we like better than ESSA Pharma
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- 3 Volatility ETFs to Help You Profit from Market Chaos
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Lam Research: Is a NAND Upgrade Cycle the Next Growth Catalyst?
- Why Invest in High-Yield Dividend Stocks?
- Chipotle’s Slip: A Short-Term Dip or Long-Term Opportunity?
Receive News & Ratings for ESSA Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma and related companies with MarketBeat.com's FREE daily email newsletter.